Anteris Technologies has enrolled and treated the first U.S. patients in its global PARADIGM trial, testing the DurAVR Transcatheter Heart Valve for severe aortic stenosis. This randomized trial compares DurAVR to existing TAVR devices, aiming to prove safety and effectiveness in about 1,000 patients. The trial's results will help guide future treatment decisions for aortic valve disease. The U.S. enrollment marks a key milestone following CMS reimbursement approval, expanding the trial's reach and recruitment potential.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
Chipotle Mexican Grill launched its first restaurant in Mexico on July 16 in San Pedro Garza García, Nuevo León, partnering with Alsea. This marks the beginning of Chipotle's international growth strategy in Mexico, with plans to open more locations ...
AI investment is rapidly increasing, with hyperscaler spending expected to grow from $673 billion in 2024 to $892 billion by 2028. Despite strong revenue growth from companies like Alphabet, concerns about overinvestment have caused significant marke...
Robert Half is rated a hold after Q1 due to improving staffing trends but continued weakness in Permanent Placement and pressure on Protiviti's revenue and margins. The decline in Protiviti is linked to less regulatory remediation work, only partly o...
